Abstract: As a first generation Bruton's tyrosine kinase inhibitor, ibrutinib is an oral small molecule targeted drug that has been proven to exhibit high efficacy and good safety in the treatment of B-cell lymphomas, including chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). Since ibrutinib first became available in China, increasing numbers of Chinese patients have benefited from it; however, with the increase in the number of patients, clinicians are faced with more adverse events, such as bleeding, atrial fibrillation, diarrhea, joint pain, among others, than traditional chemotherapeutic drugs. Because of the unique mechanism of action of ibrutinib, it is also necessary to pay attention to drug interactions when dealing with these adverse events. This review comprehensively summarizes the treatment strategies for ibrutinib adverse events in the literature and hopes to provide a reference for clinicians.